Unicancer

This study has two parts. First, it uses a blood test to find patients with a specific type of metastatic breast cancer who still have cancer DNA in their blood after one month of standard therapy. In the second part, those patients switch to a different drug, trastuzumab deruxte…

This study is testing whether women with a specific, very low-risk type of early breast cancer (DCIS) can safely skip whole-breast radiation after breast-conserving surgery. It aims to identify patients who are unlikely to have the cancer return, allowing them to avoid the side e…

This study is testing whether adding a highly focused, high-dose radiation treatment to standard care helps people with breast, lung, or prostate cancer that has spread to only a few bones (1-5 sites). It aims to see if this combined approach can keep the cancer from getting wors…

This study is testing if adding targeted radiation to the standard first-line treatment (chemotherapy plus immunotherapy) helps people with advanced non-small cell lung cancer live longer. It aims to see if radiation can boost the immune system's ability to fight cancer throughou…

This study is testing whether adding the drug tucatinib to standard treatments can better control breast cancer that has spread to the brain. It involves 53 adults with HER2-positive metastatic breast cancer whose cancer progressed in the brain but is stable elsewhere in the body…

This study compares two standard treatment approaches for women with advanced breast cancer that has spread to internal organs like the liver or lungs. It tests whether a combination of hormone therapy plus the drug abemaciclib works as well as or better than chemotherapy at cont…

This study is testing a drug called atezolizumab to see if it can help control muscle-invasive bladder cancer and prevent it from coming back after standard chemotherapy and radiation. It is for patients who are not eligible for or refuse major surgery to remove their bladder. Th…

This study is testing whether adding a drug called mifamurtide to standard chemotherapy after surgery helps patients with high-risk osteosarcoma (a type of bone cancer) live longer without their cancer returning. It will involve about 60 patients aged 2 to 50 who have already had…

This study is testing whether a drug called regorafenib can help control the growth of advanced bone sarcomas that have spread to other parts of the body. It involves 163 patients with specific types of bone cancer who have already tried other treatments. Participants are randoml…

This large international study is testing whether a personalized breast cancer screening plan, based on a woman's individual risk, works as well as the standard one-size-fits-all schedule. Over 53,000 women aged 40-70 will be randomly assigned to follow either their country's sta…